• Gurmehar Singh, Hyma Bamba, Pugazhendi Inban, Sai Harini Chandrasekaran, Vemparala Priyatha, Jobby John, and Priyadarshi Prajjwal.
• Cardiology, Government Medical College and Hospital, Chandigarh, India.
• Dis Mon. 2024 Oct 1; 70 (10): 101782101782.

AbstractAcute heart failure (AHF) episodes are marked by high rates of morbidity and mortality during the episode and minimal advancements in its care. Multiple biomarker monitoring is now a crucial supplementary technique in the therapy of AHF. A scientific literature search was conducted by assessing and evaluating the most pertinent research that has been published, including original papers and review papers with the use of PubMed, Medline, and Cochrane databases. Established biomarkers like natriuretic peptides (BNP, NT-proBNP) and cardiac troponins play crucial roles in diagnostic and prognostic evaluation. Emerging biomarkers such as microRNAs, osteopontin, galectin-3, ST2, and GDF-15 show promise in enhancing risk stratification and predicting adverse outcomes in HF. However, while these biomarkers offer valuable insights, their clinical utility requires further validation and integration into practice. Continued research into novel biomarkers holds promise for early HF detection and risk assessment, potentially mitigating the global burden of HF. Understanding the nuances of biomarker utilization is crucial for their effective incorporation into clinical practice, ultimately improving HF management and patient care.Copyright © 2024 Elsevier Inc. All rights reserved.

34 keywords...

hide…